1) 日本呼吸器学会薬剤性肺障害の診断・治療の手引き作成委員会. 薬剤性肺障害の診断・治療の手引き. 日本呼吸器学会. 2012 ; p.12-38.
4) http://druginserts.com/lib/rx/meds/erbitux-1/ECpi.
13) Barbara B, Kevin JH, Richard G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study. Lancet. 2019 ; 394 : 1915-28.
19) Tony S, Wu Y, Iveda K, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042) : a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 ; 393 : 1819-30.
20) Robert C, Pier LZ, Michelle AF, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017 ; 35 : 2125-32.
22) Aurelien M, Dung TL, Paolo A, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer : results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020 ; 38 : 1-10.